www.pharmaerudition.org

ISSN: 2249-3875

International Journal of Pharmaceutical Erudition

Research for Present and Next Generation

FEB. 2026

Vol: 15 Issue:04

(17-28)

ISSN 2249-3875

International Journal of Pharmaceutical Erudition

Review Article

CLINICAL TRIALS

Tailor Anjali*, Sharma Tanya, Amit

* Mewar University,Gangrar,Chittorgarh, (Rajasthan)312901.

As the main method by which novel treatment interventions are assessed for their safety, effectiveness, and general clinical utility, clinical trials are an essential component of contemporary biomedical and pharmacological research. Human subjects are used in this methodically planned research, which are carried out in compliance with strict scientific procedures and moral guidelines. Phase I studies are vital in laying the groundwork for later research, despite their small nature. Phase II studies are carried out on a wider sample of patients who usually have the condition of interest. once Phase I is successfully completed. To determine the novel intervention's effectiveness and safety on a larger scale, these randomized controlled trials (RCTs) compare it to conventional therapies or placebos. Phase III trial data serve as the foundation for regulatory submissions and approval decisions. After successful completion, the results are examined by regulatory bodies like the Central.
Phase IV trials, commonly referred to as post-marketing monitoring studies, continue clinical examination even after a treatment has received regulatory clearance. These studies encompass sizable and varied populations and are carried out in real-world environments. Monitoring long-term safety, identifying uncommon or delayed side effects, and evaluating the intervention's efficacy in regular clinical practice are the main goals.
Phase IV studies are essential for maintaining patient safety, and if new concerns are discovered, they may result in changes to treatment recommendations or regulatory measure.

Keywords: Clinical trials; Drug development; Randomized controlled trials (RCTs), Patient safety Pharmacovigilance, Regulatory approval, Good Clinical Practice (GCP)

INTRODUCTION

The foundation of evidence-based medicine is clinical trials, which serve as a vital link between research findings in the lab and their practical implementation. They are methodical, scientifically controlled studies carried out on human subjects to assess the therapeutic value, safety, and effectiveness of novel medications, medical technologies, diagnostic instruments, and therapeutic approaches. Clinical trials are essential to ensuring that new interventions fulfil strict quality and patient safety requirements before they are licensed for broad use in the modern era of health care, when innovationis quickly changing illness management.[1]

Although clinical trials have their roots in early experimental techniques, advances in science, ethics, and international regulatory frameworks have influenced their development into highly regulated and methodologically sound investigations. These days, national and international regulatory bodies like the Food and Drug Administration and the Central Drugs Standard Control Organization have set

stringent rules for conducting clinical trials. These organizations protect participant welfare and preserve the integrity of scientific findings by ensuring that all clinical trials follow established protocols. Furthermore, fundamental guidelines for human research are provided by ethical frame works like the Declaration of Helsinki, which emphasize risk minimization, informed permission, and respect for persons.[2]

Fundamentally, a clinical trial is intended to use meticulously planned procedures to address particular research problems. These investigations usually have a staged approach, starting with preclinical research and moving through several phases of human testing. From determining safety and dosage in early studies to verifying efficacy and tracking long-term impacts in later stages, each phase has a distinct function. Only interventions with a favourable risk-benefit profile are moved on to the next phase, which eventually results in regulatory approval and clinical adoption, thanks to this methodical development.[3]

The use of rigorous study designs to reduce bias and increase the dependability of results is one of the qualities that distinguish clinical trials. Randomized controlled trials (RCTs), which are frequently regarded as the gold standard in clinical research, randomly assign individuals to various study groups in order to compare results in an unbiased manner. By keeping participants and researchers from knowing which therapy is being given, blinding strategies like single-blind and double-blind trials further improve the validity of results. To produce high-quality research that can guide clinical decision- making and healthcare policy, several methodological precautions are crucial.[4]

Clinical trials have significant effects on patient care and public health in addition to their significance from a scientific standpoint. They provide patients with few or no other options hope by giving them access to cutting-edge therapies that may not yet be available through conventional therapy methods. Additionally, the information gathered from clinical trials helps to improve illness management techniques, produce clinical guidelines, and improve overall healthcare results. In this regard, clinical trials are essential lelements of a dynamic and changing healthcare system, not just research instruments.[5]

Despite their importance, clinical trials are fraught with difficulties that may affect their efficacy and efficiency. Participant recruitment and retention continue to be significant challenges, frequently impacted by elements including ignorance, practical limitations, and worries about possible dangers. Clinical trials are also resource-intensive projects that demand a large cash outlay, sophisticated infrastructure, and qualified staff. The start and

completion of studies may be further delayed by complicated regulations and drawn-out approval procedures, which would restrict the rate of medical innovation.[6]

A new era of clinical research has been ushered in by the incorporation of cutting-edge technology, which have started to solve many of these issues. Wearable technology and mobile health apps are examples of digital health solutions that make it possible to monitor patient data in realtime and enhance the precision of outcome evaluations. Decentralized clinical trials (DCTs) have boosted study population variety and access to research opportunities by enabling individuals to participate remotely. Additionally, the use of machine learning and artificial intelligence (AI) is transforming several facets of clinical trials, including data analysis and interpretation, trial design, and patient recruitment. The move toward precision or personalized medicine is another new trend in clinical research. Researchers can create targeted medicines that are customized to each patient's unique traits by utilizing genetic, molecular, and clinical data. This strategy improves patient outcomes by increasing therapeutic efficacy while lowering the possibility of side effects. The flexibility and efficiency of clinical trials are further improved by adaptive trial designs, which enable changes to research protocols depending on interim results, making them more sensitive to changing scientific discoveries.[7]

1. Types of Clinical Trials

There are many different types of clinical trials, and they are categorised according to their technique, goals, and purpose. Every kind of clinical trial is intended to address a particular

Table1: Key Components of Clinical Trials

Component	Description
Study Protocol	A detailed plan outlining objectives, methodology, and procedures
Participants	Human volunteers selected based on inclusion and exclusion criteria
Randomization	Allocation of participants into different groups to reduce bias
Blinding	Concealing treatment allocation to minimize subjective influence
Outcome Measures	Parameters used to assess the effectiveness and safety of interventions

Component	Description
Data Collection	Systematic recording of clinical observations and results
Regulatory Approval	Authorization from bodies like FDA or CDSCO before trial initiation
Ethical Oversight	Review by ethics committees to ensure participant safety and rights

scientific query and advance knowledge of illness treatment, prevention, diagnosis, or patient care in general. The main categories of clinical trials are explained in detail in this section, emphasising their importance in contemporary medical care and biological research.[8]

1.1 Treatment Trials

The most prevalent kind of clinical trials are treatment studies, which are mainly carried out to assess novel treatments, medications, medical devices, or surgical techniques. The purpose of these trials is to ascertain whether an ovel intervention is superior to current standard treatments or placebos. Innovative techniques like gene therapy, immunotherapy, or targeted drug delivery systems may be used in treatment trials. Patients who have been diagnosed with a particular illness or condition typically participate in therapy studies. , these investigations adhere to strict procedures that frequently include randomisation and blinding. Improvements in symptoms, the course of the illness, survival rates, and general quality of life are commonly measured outcomes.[9]

1.2 Trials for Prevention

The goal of prevention trials is to find ways to stop diseases from happening or lower the chance that they will recur.Both populations at high risk of developing acertain condition and healthy individuals may participate in these trials. Vaccines, nutritional supplements, lifestyle changes, and pharmaceuticals are examples of preventive measures.

A preventative study might, for instance, determine whether a vaccine can effectively lower the prevalence of infectious diseases or whether lifestyle modifications like diet and exercise can reduce the risk of chronic conditions like diabetes or cardiovascular disorders. Because they lower healthcare costs and the burden of disease, these trials are essential to public health.[10]

1.3 Trials for Diagnosis

The goal of diagnostic trials is to enhance techniques for precisely and early disease detection. These trials assess the accuracy, sensitivity, and specificity of novel diagnostic instruments, imaging technologies, biomarkers, or laboratory tests in comparison to current approaches.

Effective therapy and better patient outcomes depend on an early and precise diagnosis. Diagnostic studies provide prompt action by identifying disorders before their symptoms worsen. For example, molecular diagnostic techniques or sophisticated imaging technology can greatly improve the diagnosis of genetic abnormalities and malignancies.[11]

1.4 Trials of Screening

To find the most effective ways to identify illnesses in their early stages, frequently before symptoms manifest, screening trials are carried out. These studies evaluate the efficacy of

screening tests in lowering morbidity and mortality and usually involve large populations.

For diseases like cancer, where early discovery can greatly increase survival rates, screening studies are especially crucial. Colonoscopy for the detection of colorectal cancer and mammography for the screening of breast cancer are two examples. These studies assess the viability, cost-effectiveness, and possible hazards of screening techniques in addition to their efficacy.[12]

1.5 Trials of Quality of Life (Supportive Care)

The goal of quality-of-life trials, sometimes referred to as supportive care trials, is to enhance the comfort and wellbeing of individuals with long-term or life-threatening illnesses. The goals of these trials are to improve overall patient satisfaction both during and after therapy, manage symptoms, and minimize side effects.

Palliative care techniques, nutritional therapy, psychological support, and painmanagement techniques are some of the interventions examined in these trials. Improving the patient's quality of life and functional status is the main objective rather than necessarily curing the illness.[13]

1. Phases of ClinicalTrials

In order to address certain research issues about the safety, effectiveness, dose,and long-term effects of a novel medication or therapeutic intervention, clinical trials are carried out in a methodical and sequential fashion through various phases. By reducing risks to human subjects, these stages guarantee that only safe and efficient treatments are introduced to the market. Drug development and regulatory approval depend heavily on the phased strategy, which is a fundamental component of clinical research.[14]

Amedicationis put through a rigorous preclinical testing process inlabs and onanimal models before going into clinical trials. These investigations seek to assess the compound's pharmacokinetics, pharmacodynamics, toxicity, and biological activity. Preclinical data help assess whether the medication is appropriate for human trials and offer crucial information about the safety profile. Amedicine can only move on to human clinical trials with regulatory authorities' clearance following a successful preclinical evaluation.[15]

PhaseI Clinical Studies (Dosage and Safety)

Phase I trials are the initial phase of human subjects testing. Depending on the type of medication, a small sample of 20–100 healthy volunteers or patients are usually included in these trials. Evaluating the drug's safety, tolerability, and ideal dosage range is the main goal. Researchers examine how the medication is absorbed, distributed, metabolised, and eliminated in the body

ISSN 2249-3875

International Journal of Pharmaceutical Erudition

Table 2: Summary of Types of Clinical Trials Preclinical Research (Prior to HumanTrials)

Type of Trial	Purpose	Participants	Examples
Treatment Trials	Evaluate new drugs, therapies, or procedures	Patients with the disease	Chemotherapy, gene therapy
Prevention Trials	Prevent disease occurrence or recurrence	Healthy or high-risk individuals	Vaccines, lifestyle interventions
Diagnostic Trials	Improve disease detection methods	Suspected patients	Imaging tests, Biomarker studies
Screening Trials	Detect disease early before symptoms	Large populations	Cancer screening programs
Quality of Life Trials	Improve comfort and well-being	Patients with chronic / terminal illness	Pain management, palliative care

While keeping a watchful eye out for any negative effects.

Phase I studies offer important insights about the pharmacological behaviour of the medicine, even if its main purpose is not to evaluate efficacy. By determining safe dosage levels and potential dangers, this phase establishes the groundwork for later trials.[16]

1.1 Phase II Clinical Studies (Effectiveness and Adverse Reactions)

Phase II trials involve a greater number of participants, usually between 100 and 300 individuals with the target illness or condition. This phase's primary goal is to analyse the drug's efficacy while keeping an eye on its safety.

In this stage, researchers ascertain whether the medication has the intended therapeutic impact and pinpoint typical adverse effects. Randomised controlled designs are frequently used in phase II studies to evaluate an ovel treatment with a placebo or conventional therapy .Phase III trial design is guided by the outcomes of this phase, which aid in improving treatment regimens.[17]

1.2 Phase III Clinical Trials: Verification and Evaluation

Phase III trials are extensive research projects with at least 1,000–3,000 participants spread across several locations and centers.These studies are intended to verify the medication's effectiveness, track adverse effects, and contrast it with current conventional therapies.

In this stage, randomised controlled trials (RCTs) are frequently employed to guarantee accurate and impartial outcomes. For regulatory approval, Phase III study data is essential. The results are examined by authorities like the Central Drugs Standard Control Organization and the Food and Drug Administration to decide whether the medication is suitable for general usage.[18]

1.4 Post-Marketing Surveillance in Phase IV Clinical Trials

Following the drug's approval and marketing, Phase IV trials are carried out. These trials, which involve sizable populations, are intended to track the drug's long-term safety, efficacy, and practical performance.

This stage aids in locating uncommon or delayed side effects that might not have shown up in previous trials. Additionally, it offers important details about how the medication is used in various clinical settings and demographics.

Post-marketing surveillance guarantees ongoing assessment of the drug's benefit-risk profile and, if required, may result in modifications to usage instructions or regulatory measures. .[19]

2. Clinical Trial Design

A crucial component of biomedical research is clinical trial design, which establishes how a study is set up to address certain research objectives while guaranteeing validity, reliability, and ethical integrity.A well-designed clinical study guarantees that the findings can be applied to a larger population while minimising bias and maximising data accuracy. A clinical trial's methodology, participant selection, intervention tactics, and outcome evaluation are all carefully planned.In order to guarantee that the results are both ethically and scientifically valid, it also takes statistical considerations and legal criteria into account.[20]

2.1 The Significance of Clinical Trial Design

The quality and reliability of a clinical trial's results are directly impacted by its design. Inaccurate results, resource waste, and possible participant damage can result from poorly planned experiments.

As a result, researchers must carefully choose suitable study designs that support the trial's goals. A strong design guarantees that the results are genuinely attributable to the intervention under test and are not impacted by biases or outside influences.[21]

3. Ethical Considerations in Clinical Trials

All clinical trials are built on ethical principles, which guarantee that human subjects' rights, dignity, safety, and wellbeing are upheld during the whole study process.

Following ethical guidelines is crucial to preserving public confidence, scientific integrity, and legal compliance because clinical trials directly involve human beings. International and national ethical principles provide an organised foundation for carrying out ethical and compassionate research.

3.1 The Value of Clinical Trial Ethics

Clinical trial ethics guarantee that research is carried out with consideration for human life and personal autonomy. Volunteers frequently do so in the hope that their participation will advance science without putting them in needless danger.

By balancing the possible advantages of research with its risks, ethical considerations

help guarantee that no volunteer is taken advantage of or harmed excessively.

Strict criteria like the Declaration of Helsinki were developed as a result of significant infractions caused by a lack of ethical control in the past. These frameworks stress the importance of accountability, transparency, and participant protection.[22]

3.2 Role of Ethics Committees (IRBs)

Institutional Review Boards (IRBs), also known as ethics committees, are essential to the management of clinical trials.

Before the experiment starts, these impartial organisations examine research protocols to make sure that ethical guidelines are followed.

IRBs assess:

- Risk-benefit ratios
- Informed consent processes
- Participant selection
- Data protection protocols

They also monitor ongoing trials to ensure continued ethical compliance.[23]

3.3 Ethical and Regulatory Guidelines

International and national ethical standards regulate clinical trials to guarantee uniformity and responsibility.

Table 3: Overview of Clinical Trial Phases

Phase	Participants	Primary Objective	Key Outcome
Preclinical	Laboratory & Animals	Safety, toxicity, biological activity	Basis for human trials
Phase I	20–100	Safety, dosage	Safe dose range identified
Phase II	100–300	Efficacy, side effects	Preliminary effectiveness established
Phase III	1,000–3,000+	Confirm efficacy, compare treatments	Approval for marketing
Phase IV	Thousands	Long-term safety, real-world effects	Ongoing safety monitoring

Table 4: Comparison of Clinical Trial Designs

Design Type	Key Feature	Advantages	Limitations
Randomized Controlled	Random allocation	High reliability, reduces bias	Expensive, time-consuming
Observational Study	No intervention	Real-world data	Higher risk of bias
Blinded Study	Concealed treatment allocation	Reduces subjective bias	Complex to implement
Placebo-Controlled	Uses inactive comparator	Accurate efficacy measurement	Ethical concerns
Crossover Design	Participants receive multiple treatments	Reduces variability	Not suitable for all diseases
Adaptive Design	Flexible protocol	Efficient, faster results	Complex statistical analysis

The Declaration of Helsinki provides a thorough set of guidelines for using human subjects in medical research. Regulatory bodies like the Central Drugs Standard Control Organization (CDSCO) and the Food and Drug Administration (FDA) uphold ethical principles and approve clinical trials before they begin.[24]

4. Regulatory Framework

A crucial part of biomedical research is the regulatory system that oversees clinical trials, guaranteeing that investigations are carried out in a way that is safe, moral, and supported by science.

These rules are put in place by national and international agencies to safeguard participants' rights, safety, and welfare while also guaranteeing the validity and dependability of clinical data. Regulatory supervision starts even before a clinical trial is started and lasts the whole duration of the investigation, from data reporting and post-marketing surveillance to protocol creation and approval. [25]

Harmonised standards like Good Clinical Practice (GCP), which offer a consistent framework for planning, carrying out, documenting, and reporting clinical research, serve as global guidelines for clinical trials. By ensuring that studies are carried out uniformly throughout various regions, these rules promote global cooperation and data acceptance.

The necessity of participant protection, informed consent, and scientific integrity in all clinical trials is further supported by ethical standards found in texts such as the Declaration of Helsinki.

The Food and Drug Administration, which is in charge of approving and monitoring new medications, biologics, and medical devices, regulates clinical trials in the United States. Sponsors must file an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application, which includes comprehensive details on preclinical research, study design, and safety precautions, prior to starting a clinical trial. To decide whether the trial may move forward, the FDA examines this data. [26]

The Central Drugs Standard Control Organization, which is part of the Ministry of Health and Family Welfare of India, is the regulatory body in charge of clinical trials. Clinical study approval and conduct are governed by the Drugs and Cosmetics Act and Rules, which are enforced by the CDSCO.

Before starting a trial, sponsors must get approval from the Drug Controller General of India (DCGI). Furthermore, clinical studies must be registered in the Clinical Trials Registry of India (CTRI), which encourages responsibility and openness in research.

Before a trial may start, regulatory frameworks also demand clearance from Institutional Review Boards (IRBs) or Institutional Ethics

Committees (IECs). These impartial organisations examine study procedures to make sure that participant rights are upheld, dangers are reduced, and ethical requirements are fulfilled. [27]

7. Challenges in Clinical Trials

Clinical trials are crucial for generating new therapeutic interventions and advancing medical science, but they are frequently fraught with difficulties that can reduce their effectiveness, raise expenses, and postpone the release of novel therapies.

Clinical research is a difficult and resource-intensive procedure because of these difficulties, which stem from scientific, ethical, operational, financial, and regulatory complications. Improving trial design, execution, and overall success rates requires an understanding of these difficulties. [28]

Recruiting and retaining participants is one of the biggest problems in clinical trials. Strict inclusion and exclusion criteria, low patient awareness, and geographic obstacles frequently make it challenging to enrol a sufficient number of eligible participants within a predetermined timeframe.

The lengthy and expensive nature of clinical trials is another significant obstacle. A significant financial commitment is needed to conduct a clinical research, including expenses for staff, infrastructure, data administration, monitoring, and regulatory compliance.

Particularly, Phase III trials, which involve sizable populations at numerous locations, might take several years to finish. These exorbitant expenses and protracted schedules can stifle creativity and restrict the capacity of smaller organisations to carry out research.

Significant obstacles are also presented by ethical and regulatory issues. Strict regulations set by regulatory bodies like the Food and Drug Administration and the Central Drugs Standard Control Organization must be followed in clinical studies. Although these rules are necessary to guarantee participant safety and data integrity, navigating them can be difficult and time-consuming. [29-33]

Conclusion

A crucial component of contemporary medical research, clinical trials offer the scientific proof needed to guarantee that novel medications, treatments, and medical procedures are secure, efficient, and appropriate for broad clinical application.

Clinical trials convert fundamental scientific findings into useful medical solutions that improve patient outcomes and quality of life through a systematic and rigorous methodology. Every stage of a clinical trial, from preclinical research to post-marketing surveillance, offers important information about the effectiveness, safety, and long-term effects of therapeutic interventions.

Clinical trial success is dependent on a number

of interrelated criteria, such as strong research design, adherence to ethical standards, and regulatory framework compliance.

Clinical trials confront a number of obstacles despite their crucial significance, such as hurdles in recruiting participants, high expenses, complicated regulatory regulations, and problems with data administration. These difficulties may restrict access to cutting-edge therapy and postpone the creation of novel remedies.

However, technological developments like artificial intelligence, decentralised clinical trials, and digital health tools are assisting in resolving these problems and enhancing the effectiveness and accessibility of clinical research.

Personalised medicine and patient-centric methods, which seek to customise therapies to each patient's unique traits, have received more attention in recent years. Clinical trials are being designed and conducted differently as a result of this change, becoming more flexible, inclusive, and patient-centered.

Furthermore, there is increasing international cooperation between researchers and regulatory agencies.

REFERENCE

1. Friedman, L. M., Furberg, C. D., & DeMets, D. L. (2015). Fundamentals of Clinical Trials (5th ed.). Springer.

2. Pocock, S. J. (2013). Clinical Trials: A Practical Approach. Wiley.

3. Chow, S. C., & Liu, J. P. (2014). Design and Analysis of Clinical Trials (3rd ed.). Wiley.

4. Piantadosi, S. (2017). Clinical Trials: A Methodological Perspective (3rd ed.). Wiley.

5. Meinert, C. L. (2012). Clinical Trials Handbook. Oxford University Press.

6. ICH Harmonised Guideline. (2016). Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2).

7. World Medical Association. (2013). Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA, 310(20), 2191–2194.

8. Food and Drug Administration. (2020). Guidance for Industry: Clinical Trial Endpoints.

9. Central Drugs Standard Control Organization. (2019). Guidelines for Clinical Trials in India.

10. Hulley, S. B., et al. (2013). Designing Clinical Research (4th ed.). Lippincott Williams & Wilkins.

11. Sackett, D. L. (1997). Evidence-based medicine. BMJ, 312(7023), 71–72.

12. Bothwell, L. E., Greene, J. A., Podolsky, S. H., & Jones, D. S. (2016). Assessing the gold standard. New England Journal of Medicine, 374(22), 2175–2181.

13. Ioannidis, J. P. A. (2005). Why most published research findings are false. PLoS Medicine, 2(8), e124.

14. Collins, R. (2001). What makes a good clinical trial? BMJ, 322(7297), 1099–1100.

15. Califf, R. M. (2016). Clinical trials bureaucracy. JAMA, 316(7), 679–680.

16. Emanuel, E. J., et al. (2000). What makes clinical research ethical? JAMA, 283(20), 2701.

17. Grady, C. (2015). Enduring and emerging challenges of informed consent. New England Journal of Medicine, 372(9), 855–862.

18. Katz, R. (2004). FDA approval process. Nature Reviews Drug Discovery, 3(3), 253–55.

19. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation costs. Journal of Health Economics, 47, 20–33.

20. van Norman, G. A. (2016). Phase I trials. JACC: Basic to Translational Science, 1(3), 170–179.

21. Ford, J. G., et al. (2008). Barriers to clinical trial participation. JAMA, 300(13), 1523–1531.

22. Gul, R. B., & Ali, P. A. (2010). Clinical trials: The challenge of recruitment. Journal of Clinical Nursing, 19(1–2), 227–233.

23. Huang, G. D., et al. (2018). Clinical trials recruitment planning. Contemporary Clinical Trials, 66, 74–79.

24. Corrigan-Curay, J., Sacks, L., & Woodcock, J. (2018). Real-world evidence New England Journal of Medicine, 378(23), 2293–97.

25. Sherman, R. E., et al. (2016). Use of real-world evidence. New England Journal of Medicine, 375(23), 2293–2297.

26. Eichler, H. G., et al. (2012). Adaptive trial design. Nature Reviews Drug Discovery, 11(7), 507–519.

27. Chow, S. C., Chang, M., & Pong, A. (2005). Adaptive design methods. Journal of Biopharmaceutical Statistics, 15(4), 575–591.

28. Dorsey, E. R., et al. (2020). Decentralized clinical trials. New England Journal of Medicine, 382(23), 2195–2197.

29. Izmailova, E. S., et al. (2018). Digital health technologies. Clinical Pharmacology & Therapeutics, 104(3), 409–412.

30. Topol, E. (2019). Deep Medicine. Basic Books.

31. Ashley, E. A. (2016). Precision medicine. JAMA, 316(20), 2119–20.

32. Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. New England Journal of Medicine, 372(9), 793–795.

33. Wicks, P., et al. (2015). Accelerated clinical discovery using patient-reported data. Journal of Medical Internet Research, 17(1), e20.

.

Conflict of Interest

The authors declare that they have no conflict of interest